Abstract
Membrane disrupting lytic peptides are abundant in nature and serve insects, invertebrates, vertebrates and humans as defense molecules. Initially, these peptides attracted attention as antimicrobial agents; later, the sensitivity of tumor cells to lytic peptides was discovered. In the last decade intensive research has been conducted to determine how lytic peptides lyse bacteria and tumor cells. A number of synthetic peptides have been designed to optimize their antibiotic and anti-tumor properties and improve their therapeutic capabilities. The sequences of α-helical cationic membrane disrupting peptides has been discussed, their proposed mechanisms of action reviewed, and their roles in cell selectivity and tumor cell destruction considered. Parameters important for the selection and design of lytic peptides for cancer treatments include increased activities against tumor cells, low cytolytic activities to normal mammalian cells and erythrocytes. The conjugation of lytic peptides with hormone ligands and the production of pro-peptides provide methods for targeting of cancer cells. The therapeutic possibilities in cancer treatment by targeted lytic peptides are broad and offer improvement to currently used chemotherapeutical drugs. Lytic peptides interact with the tumor cell membrane within minutes, and their activity is independent of multi-drug resistance. Lytic peptide-chorionic gonadotropin (CG) conjugates destroy primary tumors, prevent metastases and kill dormant and metastatic tumor cells. These conjugates do not destroy vital organs; they are not antigenic, and are more toxic to tumor cells than to non-malignant cells.
Keywords: lytic peptide, antitumoral drugs, cancer treatment, cell selectivity, conjugated lytic peptides
Current Pharmaceutical Design
Title: Membrane Disrupting Lytic Peptides for Cancer Treatments
Volume: 10 Issue: 19
Author(s): Carola Leuschner and William Hansel
Affiliation:
Keywords: lytic peptide, antitumoral drugs, cancer treatment, cell selectivity, conjugated lytic peptides
Abstract: Membrane disrupting lytic peptides are abundant in nature and serve insects, invertebrates, vertebrates and humans as defense molecules. Initially, these peptides attracted attention as antimicrobial agents; later, the sensitivity of tumor cells to lytic peptides was discovered. In the last decade intensive research has been conducted to determine how lytic peptides lyse bacteria and tumor cells. A number of synthetic peptides have been designed to optimize their antibiotic and anti-tumor properties and improve their therapeutic capabilities. The sequences of α-helical cationic membrane disrupting peptides has been discussed, their proposed mechanisms of action reviewed, and their roles in cell selectivity and tumor cell destruction considered. Parameters important for the selection and design of lytic peptides for cancer treatments include increased activities against tumor cells, low cytolytic activities to normal mammalian cells and erythrocytes. The conjugation of lytic peptides with hormone ligands and the production of pro-peptides provide methods for targeting of cancer cells. The therapeutic possibilities in cancer treatment by targeted lytic peptides are broad and offer improvement to currently used chemotherapeutical drugs. Lytic peptides interact with the tumor cell membrane within minutes, and their activity is independent of multi-drug resistance. Lytic peptide-chorionic gonadotropin (CG) conjugates destroy primary tumors, prevent metastases and kill dormant and metastatic tumor cells. These conjugates do not destroy vital organs; they are not antigenic, and are more toxic to tumor cells than to non-malignant cells.
Export Options
About this article
Cite this article as:
Leuschner Carola and Hansel William, Membrane Disrupting Lytic Peptides for Cancer Treatments, Current Pharmaceutical Design 2004; 10 (19) . https://dx.doi.org/10.2174/1381612043383971
DOI https://dx.doi.org/10.2174/1381612043383971 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy
Current Cancer Drug Targets Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Synthesis, Characterization, Antimycobacterial and Anticancer Evaluation of New 1,2,4-Triazole Derivatives
Letters in Drug Design & Discovery The Role of Exosomes and Exosome-derived microRNAs in Atherosclerosis
Current Pharmaceutical Design p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Interleukin 2 in Cancer Therapy
Current Medicinal Chemistry The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Current Pharmaceutical Design Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery The Design, Synthesis and Application of Stereochemical and Directional Peptide Isomers: A Critical Review
Current Protein & Peptide Science Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment
Recent Patents on Nanomedicine Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Development of Novel Therapeutic Drugs in Humans from Plant Antimicrobial Peptides
Current Protein & Peptide Science Caffeic Acid, A Versatile Pharmacophore: An Overview
Mini-Reviews in Medicinal Chemistry Synthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery Immunogenicity, Immunopathogenicity, and Immunotolerance in One Graph
Anti-Cancer Agents in Medicinal Chemistry <i>In Silico</i> Study Examining New Phenylpropanoids Targets with Antidepressant Activity
Current Drug Targets